A systematic review of the safety of topical therapies for atopic dermatitis
- PMID: 17223859
- DOI: 10.1111/j.1365-2133.2006.07538.x
A systematic review of the safety of topical therapies for atopic dermatitis
Abstract
Background: The safety of topical therapies for atopic dermatitis (AD), a common and morbid disease, has recently been the focus of increased scrutiny, adding confusion as how best to manage these patients.
Objectives: The objective of these systematic reviews was to determine the safety of topical therapies for AD.
Methods: Databases searched included: OVID Medline, Medline In-Process and Other Non-Indexed Citations, Embase, and the Cochrane Central Register of Controlled Trials. In addition to the articles identified by this search, investigators were also referred to a list of links (most recently updated 25 September 2005) to recent Food and Drug Administration (FDA) studies, reports and meetings regarding the topical calcineurin inhibitors for further potential references. Only fully published papers available in English and data obtained from FDA sites were included. Furthermore, the criteria for inclusion and exclusion for each systematic review were further evaluated at a meeting of all of the content and evidence-based medicine experts participating in this process and alteration of the inclusion criteria was done at that time when it was felt necessary to avoid inclusion of lower-quality data in the review. Qualitative review of the abstracted data was performed and reviewed at a meeting of all of the content and evidence-based medicine experts.
Results: While systemic exposure to these topical agents does occur, physiological changes appear to be uncommon and systemic complications rare and have only been found with use of topical corticosteroids.
Conclusions: Based on the data that are available the overall safety of AD therapies appears to be good with the only documented systemic side-effects of therapy those occasionally seen with use of topical corticosteroids.
Similar articles
-
Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis.J Am Acad Dermatol. 2015 Jun;72(6):992-1002. doi: 10.1016/j.jaad.2015.02.1116. Epub 2015 Apr 1. J Am Acad Dermatol. 2015. PMID: 25840730 Review.
-
Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.Am J Clin Dermatol. 2012 Apr 1;13(2):113-23. doi: 10.2165/11597780-000000000-00000. Am J Clin Dermatol. 2012. PMID: 22263704 Review.
-
Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.J Dermatolog Treat. 2010 May;21(3):144-56. doi: 10.3109/09546630903401470. J Dermatolog Treat. 2010. PMID: 20394490 Review.
-
Topical corticosteroids and topical calcineurin inhibitors in the treatment of atopic dermatitis: focus on percutaneous absorption.Am J Ther. 2009 May-Jun;16(3):264-73. doi: 10.1097/MJT.0b013e31818a975c. Am J Ther. 2009. PMID: 19262357 Review.
-
What's new in the topical treatment of allergic skin diseases.Curr Opin Allergy Clin Immunol. 2014 Oct;14(5):436-50. doi: 10.1097/ACI.0000000000000093. Curr Opin Allergy Clin Immunol. 2014. PMID: 25061854 Review.
Cited by
-
Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis.J Clin Med. 2023 Oct 17;12(20):6575. doi: 10.3390/jcm12206575. J Clin Med. 2023. PMID: 37892713 Free PMC article.
-
Anti-Inflammatory Effect of Cinnamaldehyde in a Mouse Model of 2,4-Dinitrofluorobenzene-Induced Atopic Dermatitis.Indian J Dermatol. 2023 Mar-Apr;68(2):170-177. doi: 10.4103/ijd.ijd_576_22. Indian J Dermatol. 2023. PMID: 37275806 Free PMC article.
-
The efficacy and safety of lebrikizumab monotherapy for the management of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis.Front Med (Lausanne). 2023 Jan 16;9:1091271. doi: 10.3389/fmed.2022.1091271. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36726353 Free PMC article.
-
Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.JAMA Dermatol. 2023 Mar 1;159(3):255-266. doi: 10.1001/jamadermatol.2022.6192. JAMA Dermatol. 2023. PMID: 36723913 Free PMC article.
-
Topical Glucocorticoid Use and the Risk of Posttransplant Diabetes.Case Rep Endocrinol. 2023 Jan 21;2023:3648178. doi: 10.1155/2023/3648178. eCollection 2023. Case Rep Endocrinol. 2023. PMID: 36718481 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical